Venture capital firm OPV Venture Partners has appointed Carl Weissman as managing director, commencing 2009.
Weissman joined the firm in February 2007 and was responsible for digital biology, the convergence of IT, nanotechnology and biotechnology.
In addition, he will be promoted to chairman of Accelerator, a joint investment vehicle focused on biotechnology opportunities, where he has served as president.
Weissman commented, ‘Since Accelerator and OVP first formed a partnership in 2004, the chemistry was there. Over the last two years in particular, my responsibilities representing OVP on the boards of exciting companies like Fate Therapeutics and Allozyne have expanded, and this formalises that reality. It also enables me to continue my active role in building the next generation of emerging biotechnology companies at Accelerator.’
‘The opportunities in digital biology are tremendous,’ said Chad Waite, managing director at OVP. ‘Furthermore, there is no one quite like Carl Weissman to enable OVP to fully capitalise on these opportunities. His level of knowledge and experience at the nexus of medicine and technology is unsurpassed.’
Copyright © 2008 newnet
You must be logged in to post a comment.